INSP

Inspire Medical Systems (INSP) shares gained 47.8% over three months as reimbursement uncertainty eases following new CPT code approvals and better-than-expected Q2 results. The company reported $200.6M in revenues and 14 cents adjusted EPS, while Project Horizon aims to redirect $30M in annualized savings toward growth initiatives. However, near-term sales remain disrupted and full execution risks persist.

Tempus AI demonstrated improving operating leverage in Q2 2026 with 22% revenue growth to $382.5M and adjusted EBITDA reaching $8M (a $13.6M improvement). The company completed a $460M convertible notes offering expected to reduce annual interest expenses by over $30M. Tempus raised its 2026 revenue guidance to $1.595-$1.605B while maintaining adjusted EBITDA guidance of $65M, supporting its goal of achieving positive free cash flow by year-end 2026.

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.